{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:23:14Z","timestamp":1782307394694,"version":"3.54.5"},"reference-count":40,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Patients with glucocorticoid-dependent Duchenne muscular dystrophy (DMD) have increased fracture risk and reduced bone mineral density (BMD), often precipitating mobility loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate use of zoledronic acid (ZA) in DMD in improving BMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two arm, parallel, randomized controlled trial, set in pediatric hospitals across Australia and New Zealand. Sixty-two (31 per arm) boys with glucocorticoid-dependent DMD between 6 and 16 years were included. Five ZA infusions (0.025 mg\/kg at months 0, and 3, and 0.05 mg\/kg at months 6, 12, and 18), plus calcium and vitamin D, were compared with calcium and vitamin D alone. The main outcome measures were change in lumbar spine (LS) BMD raw and Z-score by dual energy absorptiometry x-ray (DXA) at 12 and 24 months, secondary outcomes assessing mobility, fracture incidence, bone turnover, peripheral quantitative computerized (pQCT) and pain scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At 12 and 24 months, mean difference in changes of LS BMD Z-score from baseline was 1.2 SD (95% CI 0.9-1.5), higher by 19.3% (14.6-24.0) and 1.4 SD (0.9-1.9), higher by 26.0% (17.4-34.5) in ZA than control arms respectively (both P &amp;lt; .001). Five controls developed Genant 3 vertebral fractures, 0 in the ZA arm. Mobility, pain, and bone turnover markers were similar between arms at 12 and 24 months. Trabecular BMC and vBMD pQCT at radius and tibia were greater at 12 months in the ZA cohort than control; the evidence for this difference remained at 24 months for radius but not tibia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ZA improved BMD in glucocorticoid-dependent DMD boys. Although the small cohort precluded demonstrable fracture benefit, improved BMD might reduce incident vertebral fracture.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgab302","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T15:42:26Z","timestamp":1620315746000},"page":"2328-2342","source":"Crossref","is-referenced-by-count":30,"title":["Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-6818","authenticated-orcid":false,"given":"Margaret","family":"Zacharin","sequence":"first","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Royal Children\u2019s Hospital, Parkville 3052, Victoria, Australia"},{"name":"Department of Pediatrics, University of Melbourne, Parkville 3052, Victoria, Australia"},{"name":"Department of Endocrinology, Royal Children\u2019s Hospital, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8219-1191","authenticated-orcid":false,"given":"Angelina","family":"Lim","sequence":"additional","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Royal Children\u2019s Hospital, Parkville 3052, Victoria, Australia"},{"name":"Department of Endocrinology, Royal Children\u2019s Hospital, Victoria, Australia"},{"name":"Centre for Medicine Use and Safety, Monash University, Parkville 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gryllakis","sequence":"additional","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Royal Children\u2019s Hospital, Parkville 3052, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aris","family":"Siafarikas","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Perth Children\u2019s Hospital, Perth, Western Australia, Australia"},{"name":"Faculty of Health and Medical Sciences, Paediatrics, The University of Western Australia, Nedlands, Western Australia, Australia"},{"name":"Institute for Health Research, University of Notre Dame, Fremantle, Western Australia, Australia"},{"name":"Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Jefferies","sequence":"additional","affiliation":[{"name":"Starship Children\u2019s health, Auckland NZ, and Liggins institute, University of Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Briody","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Children\u2019s Hospital at Westmead, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2895-3279","authenticated-orcid":false,"given":"Natasha","family":"Heather","sequence":"additional","affiliation":[{"name":"Starship Children\u2019s health, Auckland NZ, and Liggins institute, University of Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Pitkin","sequence":"additional","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Royal Children\u2019s Hospital, Parkville 3052, Victoria, Australia"},{"name":"Department of Endocrinology, Royal Children\u2019s Hospital, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaiman","family":"Emmanuel","sequence":"additional","affiliation":[{"name":"Department of Radiology, Royal Children\u2019s Hospital , Parkville 3052, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine J","family":"Lee","sequence":"additional","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Royal Children\u2019s Hospital, Parkville 3052, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Wang","sequence":"additional","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Royal Children\u2019s Hospital, Parkville 3052, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Simm","sequence":"additional","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Royal Children\u2019s Hospital, Parkville 3052, Victoria, Australia"},{"name":"Department of Pediatrics, University of Melbourne, Parkville 3052, Victoria, Australia"},{"name":"Department of Endocrinology, Royal Children\u2019s Hospital, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig F","family":"Munns","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Children\u2019s Hospital at Westmead, Sydney, Australia"},{"name":"Discipline of Paediatrics & Child Health, University of Sydney, Sydney, 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"issue":"1","key":"2021122204333175800_CIT0001","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases\u2013a world survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscul Disord."},{"issue":"4","key":"2021122204333175800_CIT0002","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JND-170280","article-title":"Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database","volume":"4","author":"Koeks","year":"2017","journal-title":"J Neuromuscul Dis."},{"issue":"3","key":"2021122204333175800_CIT0003","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pediatrneurol.2007.11.001","article-title":"Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up","volume":"38","author":"Houde","year":"2008","journal-title":"Pediatr Neurol."},{"issue":"1","key":"2021122204333175800_CIT0004","first-page":"16","article-title":"The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy","volume":"31","author":"McAdam","year":"2012","journal-title":"Acta Myol."},{"issue":"4","key":"2021122204333175800_CIT0005","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/mus.20812","article-title":"The role of corticosteroids in muscular dystrophy: a critical appraisal","volume":"36","author":"Angelini","year":"2007","journal-title":"Muscle Nerve."},{"issue":"5","key":"2021122204333175800_CIT0006","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/0009922807311732","article-title":"Bone mineral density in children exposed to chronic glucocorticoid therapy","volume":"47","author":"Cohran","year":"2008","journal-title":"Clin Pediatr (Phila)."},{"issue":"19","key":"2021122204333175800_CIT0007","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","article-title":"Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy","volume":"68","author":"King","year":"2007","journal-title":"Neurology."},{"issue":"1","key":"2021122204333175800_CIT0008","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MED.0000000000000456","article-title":"Growth, pubertal development, and skeletal health in boys with Duchenne muscular dystrophy","volume":"26","author":"Ward","year":"2019","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"issue":"1","key":"2021122204333175800_CIT0009","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01241398-200001000-00016","article-title":"Bone mineral density and fractures in boys with Duchenne muscular dystrophy","volume":"20","author":"Larson","year":"2000","journal-title":"J Pediatr Orthop."},{"key":"2021122204333175800_CIT0010","first-page":"CD010899","article-title":"Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy","volume":"1","author":"Bell","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"2021122204333175800_CIT0011","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"issue":"9","key":"2021122204333175800_CIT0012","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0883073816650034","article-title":"Fracture in Duchenne muscular dystrophy: natural history and vitamin D deficiency","volume":"31","author":"Perera","year":"2016","journal-title":"J Child Neurol."},{"issue":"9","key":"2021122204333175800_CIT0013","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc."},{"issue":"17","key":"2021122204333175800_CIT0014","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1021\/jm020819i","article-title":"Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)","volume":"45","author":"Widler","year":"2002","journal-title":"J Med Chem."},{"issue":"1","key":"2021122204333175800_CIT0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1515\/JPEM.2009.22.1.55","article-title":"Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis","volume":"22","author":"Brown","year":"2009","journal-title":"J Pediatr Endocrinol Metab."},{"issue":"2","key":"2021122204333175800_CIT0016","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/PHM.0b013e3181583ddc","article-title":"Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy","volume":"87","author":"Apkon","year":"2008","journal-title":"Am J Phys Med Rehabil."},{"issue":"1","key":"2021122204333175800_CIT0017","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mus.24991","article-title":"Prophylactic oral bisphosphonate therapy in Duchenne muscular dystrophy","volume":"54","author":"Srinivasan","year":"2016","journal-title":"Muscle Nerve."},{"issue":"5","key":"2021122204333175800_CIT0018","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jbmr.2756","article-title":"Histomorphometry and bone matrix mineralization before and after bisphosphonate treatment in boys with Duchenne muscular dystrophy: a paired transiliac biopsy study","volume":"31","author":"Misof","year":"2016","journal-title":"J Bone Miner Res."},{"key":"2021122204333175800_CIT0019","first-page":"824-824","article-title":"Changes in height and age adjusted DXA bone indices with oral bisphosphonate treatment in Duchenne muscular dystrophy","volume":"24","author":"Tian","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"2021122204333175800_CIT0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jpc.13768","article-title":"Consensus guidelines on the use of bisphosphonate therapy in children and adolescents","volume":"54","author":"Simm","year":"2018","journal-title":"J Paediatr Child Health."},{"issue":"1","key":"2021122204333175800_CIT0021","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PEC.0b013e31827b2299","article-title":"The Wong-Baker pain FACES scale measures pain, not fear","volume":"29","author":"Garra","year":"2013","journal-title":"Pediatr Emerg Care."},{"key":"2021122204333175800_CIT0022","article-title":"Randomised controlled trial evaluating the use of zoledronic acid in Duchenne Muscular dystrophy: Supplementary tables","author":"Zacharin","year":"22, 2021"},{"issue":"3","key":"2021122204333175800_CIT0023","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bone.2007.05.002","article-title":"Acute phase response and mineral status following low dose intravenous zoledronic acid in children","volume":"41","author":"Munns","year":"2007","journal-title":"Bone."},{"issue":"6","key":"2021122204333175800_CIT0024","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1365-2265.2008.03189.x","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?","volume":"68","author":"Brown","year":"2008","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2021122204333175800_CIT0025","doi-asserted-by":"crossref","article-title":"Radiographic atlas of skeletal development of the hand and wrist","author":"Greulich","DOI":"10.1097\/00000441-195909000-00030"},{"issue":"7","key":"2021122204333175800_CIT0026","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.5650110716","article-title":"Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis the Study of Osteoporotic Fractures Research Group","volume":"11","author":"Genant","year":"1996","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2021122204333175800_CIT0027","first-page":"119","article-title":"Peripheral quantitative computed tomography of the distal radius in young subjects \u2013 new reference data and interpretation of results","volume":"5","author":"Rauch","year":"2005","journal-title":"J Musculoskelet Neuronal Interact."},{"issue":"3","key":"2021122204333175800_CIT0028","first-page":"217","article-title":"Peripheral quantitative computed tomography of the proximal radius in young subjects\u2013new reference data and interpretation of results","volume":"8","author":"Rauch","year":"2008","journal-title":"J Musculoskelet Neuronal Interact."},{"issue":"2","key":"2021122204333175800_CIT0029","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jocd.2007.11.002","article-title":"Peripheral quantitative computed tomography of the tibia: pediatric reference values","volume":"11","author":"Moyer-Mileur","year":"2008","journal-title":"J Clin Densitom."},{"key":"2021122204333175800_CIT0030","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2217\/ijr.09.58","article-title":"Use of bisphosphonates in treatment of pediatric osteoporosis","volume":"4","author":"Ward","year":"2009","journal-title":"Int J Clin Rheumatol."},{"issue":"6","key":"2021122204333175800_CIT0031","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/jbmr.5650050611","article-title":"Prevention of glucocorticoid-induced osteoporosis","volume":"5","author":"Reid","year":"1990","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2021122204333175800_CIT0032","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/mus.23948","article-title":"Bone density and alendronate effects in Duchenne muscular dystrophy patients","volume":"49","author":"Houston","year":"2014","journal-title":"Muscle Nerve."},{"issue":"11","key":"2021122204333175800_CIT0033","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s00198-012-1911-3","article-title":"The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy","volume":"23","author":"Sbrocchi","year":"2012","journal-title":"Osteoporos Int."},{"issue":"7-8","key":"2021122204333175800_CIT0034","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1159\/000512730","article-title":"Outcomes of zoledronic acid use in paediatric conditions","volume":"93","author":"Lim","year":"2020","journal-title":"Horm Res Paediatr."},{"issue":"12","key":"2021122204333175800_CIT0035","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/jpc.13692","article-title":"Therapeutic options to improve bone health outcomes in Duchenne muscular dystrophy: zoledronic acid and pubertal induction","volume":"53","author":"Lim","year":"2017","journal-title":"J Paediatr Child Health."},{"issue":"Suppl 1","key":"2021122204333175800_CIT0036","first-page":"196","article-title":"Risedronate use in Duchenne muscular dystrophy: a pilot randomised control trial","volume":"82","author":"McSweeney","year":"2014","journal-title":"Horm Res Paediatr."},{"key":"2021122204333175800_CIT0037","doi-asserted-by":"crossref","DOI":"10.1159\/000508290","article-title":"Effect of testosterone treatment for delayed puberty in Duchenne muscular dystrophy","author":"Lee","year":"2020;93(2):108-118","journal-title":"Horm Res Paediatr."},{"issue":"Supplement 1","key":"2021122204333175800_CIT0038","first-page":"183","article-title":"Effect of pubertal induction bone mass accrual, in adolescent boys with Duchenne muscular dystrophy","volume":"90","author":"Zacharin","year":"2018","journal-title":"Horm Res Paediatr."},{"issue":"Suppl 1","key":"2021122204333175800_CIT0039","first-page":"176","article-title":"Treatment with zoledronic acid in children with Duchenne muscular dystrophy","volume":"86","author":"Viseras","year":"2016","journal-title":"Horm Res Paediatr."},{"issue":"1","key":"2021122204333175800_CIT0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40200-014-0109-y","article-title":"Bisphosphonate therapy in pediatric patients","volume":"13","author":"Eghbali-Fatourechi","year":"2014","journal-title":"J Diabetes Metab Disord."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab302\/38499338\/dgab302.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/8\/2328\/41848214\/dgab302.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/8\/2328\/41848214\/dgab302.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T09:53:06Z","timestamp":1672048386000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/8\/2328\/6268613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,5,6]]},"published-print":{"date-parts":[[2021,7,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab302","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740069858.793585943","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,5,6]]}}}